Author: Mary Kate Hogan

Emerging SEC Disclosure Challenges in the Life Sciences Industry

Why is the life sciences sector an area of focus for the SEC? 

The United States Securities and Exchange Commission (“SEC”) is responsible for a pivotal aspect of regulatory oversight for publicly traded life sciences companies: monitoring public disclosures about interactions with the Federal Drug Administration (“FDA”). Pharmaceutical drugs, medical devices, and other life science products are often subject to the FDA regulatory approval process, where information about progress and development can greatly affect their market status and the price of a company’s stock. Thus, life sciences companies face substantial pressure to accurately disclose information about trial outcomes and approval status, as even unintentional misrepresentations and missteps can trigger SEC investigations. Therefore, the industry must balance communicating the clinical progress of their products with protecting confidential and proprietary information, as the SEC continuously monitors disclosures to prevent insider trading and fraud. 

What are life sciences companies required to disclose?

The primary regulation established by the SEC to enforce disclosures is known as the materiality standard, which requires the timely and complete disclosure of material information through annual (10-K), quarterly (10-Q), and current (8-K) reports. Typically, the SEC considers drugs, medical devices, and other product developments material to investors as they are prone to massive valuation swings based on clinical holds or failures for approval. Life sciences companies grapple with this uncertain standard while engaged in FDA dialogue because they must prudently determine what feedback from the agency should be conveyed to investors and the SEC. During the drug approval process, when there is consistent back and forth between a company and the FDA regarding a pending application, there is no duty to disclose ordinary course interactions if they do not involve significant material conclusions or risks. Thus, there is a fine line between choosing not to disclose immaterial issues in order to avoid investor panic and misrepresenting the product’s regulatory status to the federal government.

How is the reporting landscape shifting in the industry?

The life sciences industry can be unstable and unpredictable, and conflicts are often layered where co-investments, cross-fund participation, and compensation tied to portfolio milestones are involved. To ensure adequate disclosures, regulators tend to focus on valuation pressure points including assumptions around trial outcomes or FDA approval probabilities. Because life sciences companies are particularly susceptible to insider trading risk given the amount of material non-public information (MPNI) they possess, the SEC has recently intensified its focus on the transparency of these corporations. In order to manage the uptick in enforcement, life science companies are encouraged to adopt internal policies and include contract provisions to prevent trading on MPNI and remain objective in their disclosures about FDA feedback. More proactive and fulsome risk disclosures may help to insulate industry actors from SEC or shareholder scrutiny. False or misleading statements are prohibited by federal securities laws, so companies must be weary of their continuous oversight and keep pace with evolving disclosure requirements.

What are the emerging legal risks for corporations?

If the SEC concludes that a life sciences company submitted inaccurate or misleading disclosures, harsh consequences include substantial financial sanctions, the prohibition of individuals serving as company directors or officers, and, in extreme scenarios, criminal prosecution by the Department of Justice. The FDA itself is able to inform the SEC of securities violations and share nonpublic information with them regarding life science products, particularly if public health is at risk. Even though SEC enforcement trends have recently decreased overall, pharmaceutical, life sciences, and healthcare companies face increased enforcement activity, particularly due to the growing complexity of clinical data and industry share price movement. The Commission has expressed continued interest in cases indicative of overt fraud, false or misleading disclosures causing investor harm, and individual accountability for senior leaders of corporations. Overall, the higher selectivity of SEC actions heightens risk for public company executives, calling for robust internal and disclosure controls and transparent investor and SEC communications. 

M&A Momentum in the Medical Device Industry

From EpiPen smartphone cases to portable kidney dialysis, the MedTech industry revolutionizes access to life saving care for patients. Robust market innovation has improved personalized treatments, reduced time in hospitals, and lowered healthcare costs. In the past year, high value investments and acquisitions have gained significant traction as businesses seek to leverage their portfolios to generate new solutions for healthcare providers. Over 305 acquisitions were announced in 2024, exceeding $63 billion, according to JPMorgan figures. In light of regulatory challenges and complex mega-deals, M&A legal teams have taken a leading role in facilitating these high stakes transactions, counseling clients across borders and fostering vital alliances. The strategic consolidation of smaller innovators with well-established MedTech companies catalyzes a swifter deployment and integration of new devices into health systems around the world. This article investigates driving forces behind the industry’s M&A surge and future implications across the health law landscape.

External innovation has long played a crucial role in market capitalization for leading MedTech companies, such as Johnson & Johnson, Medtronic, Stryker, Abbott Laboratories, and Boston Scientific. Although multi-billion dollar deals draw more public attention, smaller strategic opportunities have become an attractive avenue for garnering strong returns by harnessing the novel creativity of breakthrough start-ups. Specialized technologies that impact essential clinical areas, such as cardiovascular health, stroke prevention, and advanced screening and diagnostics, have grown through recent advancements in AI. In an industry hungry for innovation, competitive designs specifically related to preventative medicine and remote monitoring have become high-demand targets of M&A activity. These deals tend to offer a more cost effective method for portfolio growth and maintaining a competitive advantage, rather than developing products in-house. Law firms across the globe diligently guide corporations in navigating intricate regulatory, commercial, and ethical challenges to help bring cutting-edge products to the market.

Along with recent scientific progress, economic and political factors contribute to the rise in MedTech transactions and venture investments, such as declining interest rates and industry deregulation. From advising on intellectual property protections to litigating industry-wide resolutions, M&A lawyers assume a significant role in the oversight of successful MedTech deals. In response to modern technology, legislators continuously adjust regulations on both national and state-specific levels, requiring practitioners to adapt to ongoing changes across the industry. For example, many digital products in medicine present future challenges for safeguarding patient privacy and ensuring consumer transparency, placing a greater emphasis on compliance for market expansion in the field. In order to make products accessible in the global market, corporations must secure various approvals, often requiring the regulatory expertise and risk-averse strategies of legal counsel. Specialized knowledge about data privacy, structured finance, and market dynamics are a key backdrop of MedTech dealmaking, with the goal of delivering and implementing life changing health care devices.

With a variety of unique ideas and actors populating across the medical device industry, new and exciting products are on the horizon. Many have already accumulated data and evidence reflecting success but await FDA approval for public distribution. Because of extensive relations between physicians and medical device companies, incremental modifications are made in the research and development process to maximize potential. The emergence of “wearable” health technologies, such as electrocardiograms, glucose monitors, and AI-powered robotic prostheses, offer numerous benefits to patients by adapting to the body using real-time data and trends. Smartwatches that detect irregular heart rhythms offer a vital form of self-monitoring, as heart disease remains the leading cause of death worldwide. Certain types of paralysis and blindness, previously incurable diagnoses, are now targeted with neural implants, altering the future of regenerative medicine and stimulating cell growth. By facilitating deals between promising tech firms and far-reaching device companies, M&A has expedited patient access to remarkable tools and encouraged a competitive edge in pushing innovative boundaries.